APA (7th ed.) Citation

Ahrens, M., Haanen, J., Albiges, L., Gross Goupil, M., Boleti, E., Gravis, G., . . . Bergmann, L. (2025). 2595MO Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment. Annals of Oncology, 36, S1392. https://doi.org/10.1016/j.annonc.2025.08.3211

Chicago Style (17th ed.) Citation

Ahrens, M., et al. "2595MO Exploratory Analysis of Chromophobe Renal Cell Carcinoma in the SUNNIFORECAST Trial Comparing Ipilimumab Plus Nivolumab Vs Standard of Care as First-line Treatment." Annals of Oncology 36 (2025): S1392. https://doi.org/10.1016/j.annonc.2025.08.3211.

MLA (9th ed.) Citation

Ahrens, M., et al. "2595MO Exploratory Analysis of Chromophobe Renal Cell Carcinoma in the SUNNIFORECAST Trial Comparing Ipilimumab Plus Nivolumab Vs Standard of Care as First-line Treatment." Annals of Oncology, vol. 36, 2025, p. S1392, https://doi.org/10.1016/j.annonc.2025.08.3211.